The National Health Fund (NFZ) spent PLN 10.9bn (€2.6bn) on drug reimbursement in January-November 2017, an increase of 4% compared with the corresponding period of 2016. The amount represents 88.9% of the NFZ’s most recent estimate of its drug reimbursement spending in the full year, i.e. PLN 12.3bn (€2.9bn).
Expenditures on the reimbursement of medicines, foods for particular nutritional uses and medical devices available upon prescription in the pharmacy channel amounted to PLN 7.5bn (€1.8bn) in January-November 2017, an increase of 2.4% year on year. The amount constitutes 91.3% of the full-year estimate.
Reimbursement via drug programmes totalled PLN 2.8bn (€662m) and was 10% higher than in January-November 2016. The amount represents 84.2% of a full-year estimate of PLN 3.3bn (€787m).
Expenditures on chemotherapy drugs came to nearly PLN 573m (€137m), up 5% year on year. The amount represents 84.7% of the full-year estimate (PLN 676m or €162m).
|NFZ spending on drug reimbursement (PLN m), change (%, y-o-y) and its share (%) in planned 2017 budget (PLN m), January-November 2016 and 2017|
|PMR based on NFZ, 2018|
|Specification||Jan-Nov 2016||Jan-Nov 2017||Change||Planned budget for 2017||Spending in Jan-Nov 2017 as a percentage of planned budget|
|Medicines, foods for particular nutritional uses and medical devices available upon prescription in the pharmacy channel||7,353.78||7,530.87||2.4%||8,251.48||91.27%|
|Reimbursement via drug programmes||2,515.48||2,772.44||10.2%||3,294.21||84.16%|